Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Oral anticoagulation therapy in the setting of liver disease86
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook54
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond51
Pharmacotherapy developments in autophagy inhibitors for bladder cancer46
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy45
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis41
Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management39
Pivmecillinam: past, present, and future39
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy38
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten31
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis31
Current treatment options for Mycobacterium marinum cutaneous infections30
Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation29
How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?28
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives27
Evaluating linaclotide for the treatment of irritable bowel syndrome with constipation in children and adolescents27
Selecting optimal therapy in the evolving therapeutic landscape of metastatic pheochromocytoma and paraganglioma26
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges25
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease25
Wound healing pharmacotherapies: what can we expect for 2026?25
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan24
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants23
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma23
0.12786507606506